{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:13:23Z","timestamp":1767388403091,"version":"3.48.0"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104943","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:40:18Z","timestamp":1757781618000},"page":"104943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Predictors of first line treatment failure in classic Hodgkin lymphoma: A comprehensive review"],"prefix":"10.1016","volume":"216","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9390-5645","authenticated-orcid":false,"given":"Mohamed Nazem","family":"Alibrahim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1942","authenticated-orcid":false,"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-639X","authenticated-orcid":false,"given":"Antonino","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104943_bib1","article-title":"High-Dose therapy and autologous hematopoietic progenitor cells transplantation for recurrent or refractory hodgkin's lymphoma: analysis of king hussein cancer center results and prognostic variables","volume":"2012","author":"Abdel-Rahman","year":"2012","journal-title":"ISRN Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib2","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical hodgkin's lymphoma: a retrospective, european, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib3","article-title":"The outcome of hodgkin lymphoma with reference to prognostic markers","volume":"14","author":"Ahmed","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.critrevonc.2025.104943_bib4","article-title":"Interim PET-results for prognosis in adults with hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies","author":"Aldin","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.critrevonc.2025.104943_bib5","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/cancers15041063","article-title":"FDG-PET\/CT in the monitoring of lymphoma immunotherapy response: current status and future prospects","volume":"15","author":"Al-Ibraheem","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104943_bib6","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.semnuclmed.2022.10.006","article-title":"PET\/CT in hodgkin lymphoma: an update","author":"Al-Ibraheem","year":"2023","journal-title":"Semin. Nucl. Med. Elsevier"},{"key":"10.1016\/j.critrevonc.2025.104943_bib7","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.3390\/cancers16234070","article-title":"Pathobiological features and therapeutic opportunities linked to TNF family member expression in classic hodgkin lymphoma","volume":"16","author":"Alibrahim","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104943_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101271","article-title":"Classic hodgkin lymphoma: pathobiological features that impact emerging therapies","author":"Alibrahim","year":"2025","journal-title":"Blood Rev."},{"key":"10.1016\/j.critrevonc.2025.104943_bib9","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response\u2013adapted treatment in stage I and II hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib10","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104943_bib12","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2105822118","article-title":"Single-cell profiling reveals the importance of CXCL13\/CXCR5 axis biology in lymphocyte-rich classic hodgkin lymphoma","volume":"118","author":"Aoki","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.critrevonc.2025.104943_bib13","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1182\/blood-2023-174139","article-title":"Multi-dimensional molecular and tumor-microenvironment analysis of classic hodgkin lymphoma","volume":"142","author":"Aoki","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib14","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1200\/JCO.23.01115","article-title":"Spatially resolved tumor microenvironment predicts treatment outcomes in relapsed\/refractory hodgkin lymphoma","volume":"42","author":"Aoki","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-019-03893-7","article-title":"The classic prognostic factors in advanced Hodgkin\u2019s lymphoma patients are losing their meaning at the time of Pet-guided treatments","volume":"99","author":"Bari","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00277-019-03893-7","article-title":"The classic prognostic factors in advanced hodgkin's lymphoma patients are losing their meaning at the time of Pet-guided treatments","volume":"99","author":"Bari","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib17","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1080\/10428194.2018.1492123","article-title":"Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical hodgkin lymphoma","volume":"60","author":"Bessi","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2025.104943_bib18","article-title":"Real-World outcomes of hodgkin lymphoma: a Multi-Centric registry from India","volume":"11","author":"Bhurani","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib19","article-title":"Clinical use of circulating tumor DNA analysis in patients with lymphoma","author":"Bisig","year":"2024","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104943_bib21","doi-asserted-by":"crossref","first-page":"742","DOI":"10.3390\/cancers14030742","article-title":"The grey zones of classic hodgkin lymphoma","volume":"14","author":"Bosch-Schips","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104943_bib22","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.1182\/blood-2024-204572","article-title":"Profile of inflammatory biomarkers in hodgkin lymphoma. Differences between HIV-Negative and HIV-Positive patients","volume":"144","author":"Botafogo","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib23","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0140-6736(20)32207-8","article-title":"Classical hodgkin lymphoma","volume":"398","author":"Brice","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104943_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/cancers13040682","article-title":"Genomic landscape of hodgkin lymphoma","volume":"13","author":"Brune","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104943_bib25","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1097\/MPH.0000000000001811","article-title":"Coincidental expression of classic hodgkin lymphoma and neurofibromatosis type I and literature review","volume":"43","author":"Cabrera","year":"2021","journal-title":"J. Pedia Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/bjh.19162","article-title":"Baseline circulating tumour DNA and interim PET predict response in relapsed\/refractory classical hodgkin lymphoma","volume":"204","author":"Calabretta","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical hodgkin lymphoma monitoring: a prospective study","volume":"106","author":"Camus","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104943_bib28","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1200\/JCO.21.01777","article-title":"Positron emission tomography\u2013driven strategy in advanced hodgkin lymphoma: prolonged follow-up of the AHL2011 phase III lymphoma study association study","volume":"40","author":"Casasnovas","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib29","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1200\/JCO.2017.72.7925","article-title":"Prognostic model to predict post-autologous stem-cell transplantation outcomes in classical hodgkin lymphoma","volume":"35","author":"Chan","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41375-019-0541-6","article-title":"Genotyping circulating tumor DNA of pediatric hodgkin lymphoma","volume":"34","author":"Desch","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.104943_bib31","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3324\/haematol.2011.056051","article-title":"Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and\/or refractory hodgkin's lymphoma responding to prior salvage therapy","volume":"97","author":"Devillier","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104943_bib32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.13634","article-title":"Evaluation of the international prognostic score (IPS-7) and a simpler prognostic score (IPS-3) for advanced hodgkin lymphoma in the modern era","volume":"171","author":"Diefenbach","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.2023020959","article-title":"Elevated serum TARC levels precede classic hodgkin lymphoma diagnosis by several years","volume":"142","author":"Diepstra","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib34","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1093\/annonc\/mdh465","article-title":"Treatment of stage I and II hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study","volume":"15","author":"Dominguez","year":"2004","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib35","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/jha2.432","article-title":"Blood-circulating EV-miRNAs, serum TARC, and quantitative FDG-PET features in classical hodgkin lymphoma","volume":"3","author":"Drees","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.critrevonc.2025.104943_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12121","article-title":"Extracellular vesicle miRNA predict FDG-PET status in patients with classical hodgkin lymphoma","volume":"10","author":"Drees","year":"2021","journal-title":"J. Extracell. Vesicles"},{"key":"10.1016\/j.critrevonc.2025.104943_bib37","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2023-173320","article-title":"Development and validation of the Early-Stage hodgkin lymphoma (HL) international prognostication index (E-HIPI): a report from the hodgkin lymphoma international study for individual care (HoLISTIC) consortium","volume":"142","author":"Evens","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.23.01745","article-title":"Long-term follow-up of the response-adapted intergroup EORTC\/LYSA\/FIL H10 trial for localized hodgkin lymphoma","volume":"42","author":"Federico","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib39","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jha2.826","article-title":"Circulating tumor DNA for monitoring classic hodgkin lymphoma patients: correlation with FDG-PET\/CT","volume":"5","author":"Fernandez","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.critrevonc.2025.104943_bib40","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/bjh.18083","article-title":"Guideline for the first-line management of classical hodgkin lymphoma - a British society for haematology guideline","volume":"197","author":"Follows","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41375-023-02064-y","article-title":"Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable hodgkin lymphoma","volume":"38","author":"Fuchs","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2025.104943_bib42","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/bjh.19657","article-title":"Toward a paradigm shift in prognostication and treatment of early-stage hodgkin lymphoma","volume":"205","author":"Gallamini","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/hon.19_2879","article-title":"Baseline metabolic tumor volume and IPS predict ABVD failure in advanced-stage hodgkin lymphoma with a negative interim PET scan after 2 chemotherapy cycles. A retrospective analysis from the GITIL\/FIL HD0607 trial","volume":"39","author":"Gallamini","year":"2021","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib44","first-page":"862","article-title":"Unraveling the immune microenvironment in classic hodgkin lymphoma: prognostic and therapeutic implications","volume":"12","author":"Georgoulis","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104943_bib45","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3390\/biology12060862","article-title":"Unraveling the immune microenvironment in classic hodgkin lymphoma: prognostic and therapeutic implications","volume":"12","author":"Georgoulis","year":"2023","journal-title":"Biology"},{"key":"10.1016\/j.critrevonc.2025.104943_bib46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/bjh.17793","article-title":"9p24. 1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical hodgkin lymphoma: an analysis from the German hodgkin study group NIVAHL trial","volume":"196","author":"Gerhard-Hartmann","year":"2022","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hon.2295","article-title":"Independent prognostic impact of tumour-infiltrating macrophages in early-stage hodgkin's lymphoma","volume":"35","author":"Gotti","year":"2017","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib48","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1182\/blood.2023022197","article-title":"Dissection of single-cell landscapes for the development of chimeric antigen receptor t cells in hodgkin lymphoma","volume":"145","author":"Gottschlich","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib49","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/cncr.32584","article-title":"Association between facility volume and mortality of patients with classic hodgkin lymphoma","volume":"126","author":"Goyal","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2025.104943_bib50","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2023.06.005","article-title":"Clinical applications of circulating tumor DNA in hodgkin lymphoma","author":"Heger","year":"2023","journal-title":"Semin. Hematol. Elsevier"},{"key":"10.1016\/j.critrevonc.2025.104943_bib51","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1200\/JCO.23.01867","article-title":"Circulating tumor DNA sequencing for biologic classification and individualized risk stratification in patients with hodgkin lymphoma","volume":"42","author":"Heger","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib52","article-title":"SWOG S1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic hodgkin lymphoma (HL). American society","author":"Herrera","year":"2023","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib53","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"Hodgkin lymphoma, version 2.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Hoppe","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"10.1016\/j.critrevonc.2025.104943_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13045-022-01281-9","article-title":"Incidence, mortality, risk factors, and trends for hodgkin lymphoma: a global data analysis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib55","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13000-022-01272-x","article-title":"Aberrant synaptophysin expression in classic hodgkin lymphoma","volume":"17","author":"Im","year":"2022","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib56","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104943_bib57","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bbmt.2011.07.020","article-title":"Outcomes of hodgkin's lymphoma patients with relapse or progression following autologous hematopoietic cell transplantation","volume":"18","author":"Kaloyannidis","year":"2012","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.critrevonc.2025.104943_bib58","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1182\/blood-2021-147177","article-title":"Total metabolic tumor volume and tumor dissemination are independent prognostic factors in advanced hodgkin lymphoma","volume":"138","author":"Kanoun","year":"2021","journal-title":"Blood"},{"year":"2025","series-title":"Hodgkin Lymphoma (Nursing). StatPearls","author":"Kaseb","key":"10.1016\/j.critrevonc.2025.104943_bib59"},{"key":"10.1016\/j.critrevonc.2025.104943_bib60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/his.14836","article-title":"The value of thymus and activation related chemokine immunohistochemistry in classic hodgkin lymphoma diagnostics","volume":"82","author":"Kilsdonk","year":"2023","journal-title":"Histopathology"},{"key":"10.1016\/j.critrevonc.2025.104943_bib61","series-title":"Seminars in Hematology","article-title":"Molecular biomarkers in classic hodgkin lymphoma","author":"Kishida","year":"2024"},{"key":"10.1016\/j.critrevonc.2025.104943_bib62","first-page":"2273","article-title":"Outcome-based interpretation of early interim PET in advanced-stage hodgkin lymphoma","volume":"132","author":"Kobe","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib63","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.22.00947","article-title":"Positron emission Tomography-Adapted therapy in bulky stage I\/II classic hodgkin lymphoma: CALGB 50801 (Alliance)","volume":"41","author":"LaCasce","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.23.01177","article-title":"Long-term follow-up of the response-adjusted therapy for advanced hodgkin lymphoma trial","volume":"42","author":"Luminari","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101514","article-title":"Hodgkin lymphoma: a disease shaped by the tumor micro-and macroenvironment","volume":"36","author":"Masel","year":"2023","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib66","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1158\/2643-3230.BCD-22-0128","article-title":"Molecular evolution of classic hodgkin lymphoma revealed through Whole-Genome sequencing of hodgkin and reed sternberg cells","volume":"4","author":"Maura","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.critrevonc.2025.104943_bib67","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.seminoncol.2017.10.003","article-title":"Hodgkin lymphoma: a complex metabolic ecosystem with glycolytic reprogramming of the tumor microenvironment","author":"Mikkilineni","year":"2017","journal-title":"Semin. Oncol. Elsevier"},{"key":"10.1016\/j.critrevonc.2025.104943_bib68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13000-019-0912-3","article-title":"The role of CD68+ macrophage in classical hodgkin lymphoma patients from Egypt","volume":"15","author":"Mohamed","year":"2020","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib69","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical hodgkin lymphoma: the era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2025.104943_bib70","doi-asserted-by":"crossref","first-page":"450","DOI":"10.48095\/ccko2020450","article-title":"A Ukrainian multicenter prospective study of the value of PET\/CT prognostic role in primary patients with Hodgkin\u2019s lymphoma in a real-life cohort","volume":"33","author":"Novosad","year":"2020","journal-title":"Klinicka Onkologie: Casopis Ceske a Slovenske Onkologicke Spolecnosti"},{"key":"10.1016\/j.critrevonc.2025.104943_bib71","article-title":"Radiation therapy in the German hodgkin study group HD 16 and HD 17 trials: quality assurance and dosimetric analysis for hodgkin lymphoma in the modern era","volume":"8","author":"Oertel","year":"2023","journal-title":"Adv. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib72","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3960\/jslrt.24034","article-title":"Mechanisms of lymphoma-stromal interactions focusing on tumor-associated macrophages, fibroblastic reticular cells, and follicular dendritic cells","volume":"64","author":"Ohe","year":"2024","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.critrevonc.2025.104943_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54512-7","article-title":"Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic hodgkin lymphoma","volume":"15","author":"Paczkowska","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.104943_bib74","article-title":"The use of etoposide, Ara-Cytarabine, and melphalan (EAM) conditioning chemotherapy in autologous stem cell transplantation (ASCT) for a patient with relapsed hodgkin's lymphoma","volume":"2021","author":"Pangarsa","year":"2021","journal-title":"Case Rep. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib75","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024015140","article-title":"Maximum tumor diameter is associated with relapse risk in limited-stage hodgkin lymphoma: an international study","author":"Phillips","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.critrevonc.2025.104943_bib76","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20210576","article-title":"PET-guided treatment for personalised therapy of hodgkin lymphoma and aggressive non-Hodgkin lymphoma","volume":"94","author":"Phillips","year":"2021","journal-title":"Br. J. Radio."},{"key":"10.1016\/j.critrevonc.2025.104943_bib77","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1080\/10428194.2021.1957865","article-title":"Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory hodgkin lymphoma: a systematic review and meta-analysis","volume":"62","author":"Plattel","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2025.104943_bib78","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2025.104943_bib79","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/ijerph17051783","article-title":"Resources-Stratified guidelines for classical hodgkin lymphoma","volume":"17","author":"Relecom","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.critrevonc.2025.104943_bib80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-135935","article-title":"Prognostication for advanced stage hodgkin lymphoma (HL) in the modern era: a project from the hodgkin lymphoma international study for individual care (HoLISTIC) consortium","volume":"136","author":"Rodday","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib81","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.22.02473","article-title":"The advanced-stage hodgkin lymphoma international prognostic index: development and validation of a clinical prediction model from the HoLISTIC consortium","volume":"41","author":"Rodday","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib82","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib83","first-page":"1947","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115073","article-title":"Classic hodgkin lymphoma: the LYSA pragmatic guidelines","volume":"213","author":"Rossi","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104943_bib85","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00277-014-2215-9","article-title":"Brentuximab vedotin for relapsed or refractory hodgkin lymphoma: experience in Turkey","volume":"94","author":"Salihoglu","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib86","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.2016.70.9410","article-title":"Long-term follow-up of contemporary treatment in early-stage hodgkin lymphoma: updated analyses of the German hodgkin study group HD7, HD8, HD10, and HD11 trials","volume":"35","author":"Sasse","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2025.104943_bib88","first-page":"1","article-title":"Does interim PET scan after 2 cycles of ABVD predict outcome in hodgkin lymphoma? Real-world evidence","volume":"5","author":"Seshachalam","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib89","doi-asserted-by":"crossref","first-page":"6378","DOI":"10.1182\/blood-2024-212273","article-title":"Influence of gender on outcomes and palliative care utilization in patients with hodgkin's lymphoma: a retrospective study using The National inpatient sample database","volume":"144","author":"Shah","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2025.104943_bib90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12308-023-00530-1","article-title":"PD-L1 immunohistochemistry assay optimization to provide more comprehensive pathological information in classic hodgkin lymphoma","volume":"16","author":"Shi","year":"2023","journal-title":"J. Hematop"},{"key":"10.1016\/j.critrevonc.2025.104943_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.critrevonc.2025.104943_bib92","first-page":"4283","article-title":"The role of cytokines in classical hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib93","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.medj.2021.09.002","article-title":"In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin\u2019s lymphoma and facilitates ultrasensitive residual disease detection","volume":"2","author":"Sobesky","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.critrevonc.2025.104943_bib94","first-page":"2413","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib95","first-page":"1","article-title":"Topological importance of CD8+ T-cell enrichment in the tumor microenvironment of classic hodgkin lymphoma","author":"Takahashi","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib96","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/hematolrep15010012","article-title":"Post-treatment neutrophil and lymphocyte counts predict Progression-Free survival following First-Line chemotherapy in hodgkin's lymphoma","volume":"15","author":"Tan","year":"2023","journal-title":"Hematol. Rep."},{"key":"10.1016\/j.critrevonc.2025.104943_bib97","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.3390\/jcm12103498","article-title":"Assessment of response to immunotherapy in patients with hodgkin lymphoma: towards quantifying changes in tumor burden using FDG-PET\/CT","volume":"12","author":"Tutino","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.critrevonc.2025.104943_bib98","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3324\/haematol.2017.180554","article-title":"A phase II study of the oral JAK1\/JAK2 inhibitor ruxolitinib in advanced relapsed\/refractory hodgkin lymphoma","volume":"103","author":"Van Den Neste","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2025.104943_bib99","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13046-024-03108-6","article-title":"Hodgkin lymphoma and liquid biopsy: a story to be told","volume":"43","author":"Velasco-Suelto","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104943_bib100","first-page":"1","article-title":"Outcomes of refractory and relapsed hodgkin lymphoma with autologous Stem-Cell transplantation: a single institution experience","volume":"5","author":"Wali","year":"2019","journal-title":"J. Glob. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib101","first-page":"1","article-title":"Circulating tumor DNA assisting lymphoma genetic feature profiling and identification","author":"Wang","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib102","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1007\/s00277-024-05782-0","article-title":"Circulating tumor DNA assisting lymphoma genetic feature profiling and identification","volume":"103","author":"Wang","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib103","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ajh.27533","article-title":"Blood plasma methylated DNA markers in the detection of lymphoma: discovery, validation, and clinical pilot","volume":"100","author":"Witzig","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib104","article-title":"Circulating tumor DNA characteristics based on next generation sequencing and its correlation with clinical parameters in patients with lymphoma","volume":"12","author":"Wu","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib105","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/ajh.26500","article-title":"Risk stratification for relapsed\/refractory classical hodgkin lymphoma integrating pretransplant deauville score and residual metabolic tumor volume","volume":"97","author":"Yhim","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2025.104943_bib106","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/ijms25126447","article-title":"Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art","volume":"25","author":"Zanelli","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104943_bib107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.semnuclmed.2022.10.004","article-title":"Interim FDG-PET\/CT for response assessment of lymphoma","author":"Zeman","year":"2023","journal-title":"Semin. Nucl. Med. Elsevier"},{"key":"10.1016\/j.critrevonc.2025.104943_bib108","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1182\/bloodadvances.2023010024","article-title":"Significance of E-lesions in hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH","volume":"7","author":"Zijtregtop","year":"2023","journal-title":"Blood Adv."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003312?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825003312?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:09:46Z","timestamp":1767388186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825003312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":108,"alternative-id":["S1040842825003312"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104943","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of first line treatment failure in classic Hodgkin lymphoma: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104943"}}